Paolo Magni
Cited by
Cited by
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents
M Simeoni, P Magni, C Cammia, G De Nicolao, V Croci, E Pesenti, ...
Cancer research 64 (3), 1094-1101, 2004
Modelling methodology for physiology and medicine
E Carson, C Cobelli
Newnes, 2013
2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial
J Kropff, S Del Favero, J Place, C Toffanin, R Visentin, M Monaro, ...
The lancet Diabetes & endocrinology 3 (12), 939-947, 2015
A review of mixed‐effects models of tumor growth and effects of anticancer drug treatment used in population analysis
B Ribba, NH Holford, P Magni, I Trocˇniz, I Gueorguieva, P Girard, C Sarr, ...
CPT: pharmacometrics & systems pharmacology 3 (5), 1-10, 2014
Temporal data mining for the quality assessment of hemodialysis services
R Bellazzi, C Larizza, P Magni, R Bellazzi
Artificial intelligence in medicine 34 (1), 25-39, 2005
Intelligent analysis of clinical time series: an application in the diabetes mellitus domain
R Bellazzi, C Larizza, P Magni, S Montani, M Stefanelli
Artificial intelligence in medicine 20 (1), 37-57, 2000
A mathematical model to study the effects of drugs administration on tumor growth dynamics
P Magni, M Simeoni, I Poggesi, M Rocchetti, G De Nicolao
Mathematical biosciences 200 (2), 127-151, 2006
Day-and-night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: results of a single-arm 1-month experience compared with a previouslyá…
E Renard, A Farret, J Kropff, D Bruttomesso, M Messori, J Place, ...
Diabetes Care 39 (7), 1151-1160, 2016
Integrating model-based decision support in a multi-modal reasoning system for managing type 1 diabetic patients
S Montani, P Magni, R Bellazzi, C Larizza, AV Roudsari, ER Carson
Artificial intelligence in medicine 29 (1-2), 131-151, 2003
A hierarchical Naive Bayes Model for handling sample heterogeneity in classification problems: an application to tissue microarrays
F Demichelis, P Magni, P Piergiorgi, MA Rubin, R Bellazzi
BMC bioinformatics 7 (1), 1-12, 2006
Deciding when to intervene: a Markov decision process approach
P Magni, S Quaglini, M Marchetti, G Barosi
International Journal of Medical Informatics 60 (3), 237-253, 2000
Minimal model SI=0 problem in NIDDM subjects: nonzero Bayesian estimates with credible confidence intervals
G Pillonetto, G Sparacino, P Magni, R Bellazzi, C Cobelli
American Journal of Physiology-Endocrinology and Metabolism 282 (3), E564-E573, 2002
TimeClust: a clustering tool for gene expression time series
P Magni, F Ferrazzi, L Sacchi, R Bellazzi
Bioinformatics 24 (3), 430-432, 2008
Bayesian function learning using MCMC methods
P Magni, R Bellazzi, G De Nicolao
IEEE Transactions on Pattern Analysis and Machine Intelligence 20 (12), 1319á…, 1998
A stochastic model to assess the variability of blood glucose time series in diabetic patients self-monitoring
P Magni, R Bellazzi
IEEE Transactions on biomedical engineering 53 (6), 977-985, 2006
Modeling of human tumor xenografts and dose rationale in oncology
M Simeoni, G De Nicolao, P Magni, M Rocchetti, I Poggesi
Drug Discovery Today: Technologies 10 (3), e365-e372, 2013
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response
G Jannuzzi, G Gatti, P Magni, E Spina, R Pacifici, P Zuccaro, R Torta, ...
Therapeutic drug monitoring 24 (5), 616-627, 2002
Fermentation of lactose to ethanol in cheese whey permeate and concentrated permeate by engineered Escherichia coli
L Pasotti, S Zucca, M Casanova, G Micoli, MG Cusella De Angelis, ...
BMC biotechnology 17 (1), 1-12, 2017
Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach
M Rocchetti, F Del Bene, M Germani, F Fiorentini, I Poggesi, E Pesenti, ...
European Journal of Cancer 45 (18), 3336-3346, 2009
Drug and disease model resources: a consortium to create standards and tools to enhance model‐based drug development
L Harnisch, I Matthews, J Chard, MO Karlsson
CPT: Pharmacometrics & Systems Pharmacology 2 (3), 1-3, 2013
The system can't perform the operation now. Try again later.
Articles 1–20